A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 92 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 65th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Defymed · Sites in France
Ages 18+
By country, each count listing its studies:
Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 3 · Phase 3 26 · Phase 4 24
First in 1989; this study’s year is marked. 5 started in 2016.
This study's enrollment of 472 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 87 interventional studies. Of the 81 that completed or were terminated, 21 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 87 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 21st largest by enrollment of the 149 interventional ones that give a count, is one of 4 that started in 2016, is one of 54 in phase 3, and was the 191st registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
2 of the studies testing Insulin Aspart in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate efficacy and safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 472 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faster-acting insulin aspart
Drug: insulin aspart
Injected s.c. /subcutaneously (under the skin)
Injected s.c. /subcutaneously (under the skin)
Change in Glycosylated Haemoglobin (HbA1c)
Change from baseline (week 0) in HbA1c was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.
Time frame: Week 0, week 16
Change From Baseline in 1-hour PPG Increment
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, Week 16
Change From Baseline in 1,5-anhydroglucitol
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, Week 16
Change From Baseline in Time Spent in Low IG (≤3.9 mmol/L [70 mg/dL]) During CGM
Change from baseline (week 0) in low interstitial glucose (IG) (≤3.9 mmol/L \[70 mg/dL\]) during continuous glucose monitoring (CGM) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol)
Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.
Time frame: Week 16
Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes
Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) without treatment emergent severe hypoglycaemic episodes was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of IMP administration after randomisation (in week 0) and no later than one day after the last day on IMP (i.e., maximum week 16 + 1 day). The results are based on the in-trial period.
Time frame: Week 16
Change From Baseline in 30-min, 1-hour, 2-hour, 3-hour and 4-hour PPG (Meal Test)
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \[meal test\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Time frame: Week 0, week 16
Change From Baseline in 30-min, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
Change from baseline (week 0) in 30-min, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and PPG was evaluated after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Time frame: Week 0, week 16
Change From Baseline in Mean of the 7-7-9 Point Self-measured Plasma Glucose (SMPG) Profile
Change from baseline (week 0) in mean of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-7-9 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
Time frame: Week 0, week 16
Change From Baseline of the 7-7-9 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline of the 7-7-9 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline of the 7-7-9 Point SMPG Profile: Pre-prandial Plasma Glucose (PG) (Mean, Pre-breakfast, Pre-lunch, Pre-main Evening Meal)
Change from baseline (week 0) in pre-prandial PG (pre-breakfast, pre-lunch, pre-main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline of the 7-7-9 Point SMPG Profile: Fluctuation in 7-7-9 Point Profile
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-7-9 point SMPG profile at baseline (week 0) and after 16 weeks of randomisation (i.e., week 16). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline of the 7-7-9 Point SMPG Profile: in Nocturnal SMPG Measurements
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL]
Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.
Time frame: Week 16
Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia
Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] without treatment emergent severe hypoglycaemia was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. The results are based on the in-trial period.
Time frame: Week 16
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins)
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values at baseline (week 0) and after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Insulin Dose in Units/Day: Total Basal
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised trial products (faster aspart and NovoRapid®) to no later than 7 days after the day of last dose of randomised trial products.
Time frame: Week 16
Insulin Dose in Units/Day: Total Bolus
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Dose in Units/Day: Total Daily Insulin Dose
Total insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Dose in Units/Day: Individual Meal Insulin Dose
No data was collected for individual meal insulin dose.
Time frame: Week 16
Insulin Dose in Units/kg/Day: Total Basal
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Dose in Units/kg/Day: Total Bolus
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Dose in Units/kg/Day: Total Daily Insulin Dose
Total insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Dose in Units/kg/Day: Individual Meal Insulin Dose
No data was collected for individual meal insulin dose.
Time frame: Week 16
Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio
Insulin carbohydrate ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Delivery Pump Parameter: Glucose Sensitivity Factor
Glucose sensitivity factor was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Insulin Delivery Pump Parameter: Active Insulin Time
Active insulin time was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 16
Change From Baseline in Mean IG Increment (0-30 Min, 0-1 Hour and 0-2 Hours After Start of Meal) (Mean, Breakfast, Lunch and Main Evening Meal)
Change from baseline (week 0) in mean interstitial glucose (IG) increment (0-30 minutes (min), 0-1 hour (h) and 0-2 h after start of meal) (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in Mean Time to the IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)
Change from baseline (week 0) in mean time to the IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in Mean IG Peak After Start of Meal (Mean, Breakfast, Lunch and Main Evening Meal)
Change from baseline (week 0) in mean IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Percentage of Time Spent With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])
Percentage of time spent with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 16
Incidence of Episodes With IG ≤2.5, 3.0, 3.5, 3.9 mmol/L [45, 54, 63, 70 mg/dL]) and IG >10.0, 12.0, 13.9 mmol/L [180, 216, 250 mg/dL])
Incidence of episodes with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 16
Change From Baseline in Mean of the IG Profile
Change from baseline (week 0) in mean of the IG profile was evaluated after 16 weeks of randomisation. The mean of an IG profile is defined as the time integral of the profile over the profile's length, divided by the profile's length. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Percentage of Time Spent Within IG Target Range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL)
Percentage of time spent within IG target range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 16
Variation in the IG Profile
Variation in IG profile was the average absolute difference from the mean of the IG profile. Variation in the IG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 16
Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL]
Area under the curve (AUC3.9-IG) for IG ≤3.9 mmol/L \[70 mg/dL\] was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 16
Change From Baseline in AUCIG,0-15min
Change from baseline (week 0) in area under the curve for interstitial glucose (AUCIG),0-15 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in AUCIG,0-30min
Change from baseline (week 0) in AUCIG,0-30 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in AUCIG,0-1h
Change from baseline (week 0) in AUCIG,0-1 hour during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in AUCIG,0-2h
Change from baseline (week 0) in AUCIG,0-2 hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in AUCIG,0-4h
Change from baseline (week 0) in AUCIG,0-24hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in Time to the IG Peak After Start of Meal
Change from baseline (week 0) in time to the IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Change From Baseline in IG Peak After Start of Meal
Change from baseline (week 0) in IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
Time frame: Week 0, week 16
Number of Treatment Emergent Adverse Events (AEs)
Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 16. A TEAE was defined as an event that has an onset date on or after the first day of exposure to randomised treatment (in week 0), and no later than seven days after the last day of randomised treatment (i.e., maximum week 16 + 7 days). The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Infusion Site Reactions
Number of treatment emergent infusion site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
ADA classification of hypo: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG \>3.9 mmol/L with symptoms. 6. Unclassifiable. NN classification of hypo: 1. BG confirmed: PG \<3.1 mmol/L with/without symptoms. 2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with symptoms. 3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with/without symptoms. 4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypo.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 1 Hour to 2 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 1 hour to 2 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 2 to 3 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 3 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes Occurring Between 3 to 4 Hours After Start of the Meal
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 3 to 4 hours after start of the meal. The results are based on the on-treatment period.
Time frame: Weeks 0-16
Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG)
Unexplained hyperglycaemia was defined as a confirmed PG value ≥16.7 mmol/L (300 mg/dL) and was unexplained (i.e. no apparent medical, dietary, insulin dosage or pump failure reason). The results are based on the on-treatment period.
Time frame: Weeks 0-16
Change From Baseline in Physical Examination: Respiratory System
Reported results are respiratory system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Cardiovascular System
Reported results are cardiovascular system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Central and Peripheral Nervous System
Reported results are central and peripheral nervous system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Gastrointestinal System, Including the Mouth
Reported results are gastrointestinal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Musculoskeletal System
Reported results are musculoskeletal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Skin
Reported results are skin-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Physical Examination: Head, Ears, Eyes, Nose, Throat and Neck
Reported results are head, ears, eyes, nose, throat and neck-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Vital Sign: Blood Pressure
Change from baseline (week 0) in blood pressure (both systolic and diastolic) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Vital Sign: Pulse
Change from baseline (week 0) in pulse was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Screening in Electrocardiogram (ECG)
Reported results are ECG findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Screening in Fundus Photography/Fundoscopy
Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) AAbnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Haematology: Haemoglobin
Change from baseline (week 0) in haemoglobin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Haematology: Haematocrit
Change from baseline (week 0) in haematocrit was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Haematology: Erythrocytes
Change from baseline (week 0) in erythrocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Haematology: Thrombocytes
Change from baseline (week 0) in thrombocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Haematology: Leucocytes
Change from baseline (week 0) in leucocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Total Protein
Change from baseline (week 0) in total protein was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Creatinine
Change from baseline (week 0) in creatinine was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Alanine Aminotransferase (ALT)
Change from baseline (week 0) in ALT was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Aspartate Aminotransferase (AST)
Change from baseline (week 0) in AST was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Alkaline Phosphatase (ALP)
Change from baseline (week 0) in ALP was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Sodium
Change from baseline (week 0) in sodium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Potassium
Change from baseline (week 0) in potassium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Albumin
Change from baseline (week 0) in albumin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Biochemistry: Total Bilirubin
Change from baseline (week 0) in bilirubin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Urinalysis: Albumin/Creatine Ratio
Change from baseline (week 0) in albumin/creatine ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Urinalysis: Erythrocytes
Reported results are urine erythrocytes-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ and e) 3+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Urinalysis: Protein
Reported results are urine protein-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Urinalysis: Ketones
Reported results are urine ketone-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Body Weight
Change from baseline (week 0) in body weight was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Change From Baseline in Body Mass Index (BMI)
Change from baseline (week 0) in BMI was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0, week 16
Number of Change-of-infusion-sets Per Week
Number of change-of-infusion-sets per week was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
Time frame: Week 0-16
Number of Subjects With at Least One Non-routine Change-of-infusion-sets Categorised by Reasons for Change-of-infusion-sets
Number of subjects with at least one non-routine change-of-infusion-sets categorised by reasons for change-of-infusion-sets was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. Reasons for change-of-infusion-sets are categorised as follows: Category-1: A perceived occlusion by the subject Category-2: Any problems related to the infusion set Category-3: Any technical issues with the pump Category-4: Changes in the insulin solution in the infusion set or reservoir Category-5: High BG with no other explanation which made the subject change the infusion set Category-6: Infusion site reaction Category-7: Missing
Time frame: Week 0-16
The trial was conducted at 92 sites in 9 countries.as follows: Belgium (7), Canada (8), France (10), Germany (9), Netherlands (9), Russian Federation (11), Slovenia (2), United Kingdom (6), and United States (30). One (1) site in the Netherlands screened, but didn't randomise any subject.
| Milestone | Faster Aspart | NovoRapid |
|---|---|---|
| Started | 236 | 236 |
| Completed | 233 | 230 |
| Not completed | 3 | 6 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 4 |
| Withdrew: Unclassified | 2 | 0 |
Change from baseline (week 0) in HbA1c was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related subject-site contact.
| Percentage (%) of HbA1c | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 7.49 ± 0.55 | 7.49 ± 0.53 |
| Change from baseline | -0.06 ± 0.50 | -0.14 ± 0.44 |
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 4.67 ± 3.09 | 4.62 ± 3.00 |
| Change from baseline | -0.89 ± 3.44 | 0.05 ± 3.37 |
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| ug/mL | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 4.20 ± 2.34 | 4.13 ± 2.14 |
| Change from baseline | 0.14 ± 1.48 | 0.25 ± 1.42 |
Change from baseline (week 0) in low interstitial glucose (IG) (≤3.9 mmol/L \[70 mg/dL\]) during continuous glucose monitoring (CGM) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| min/day | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 85.42 ± 65.20 | 79.88 ± 60.46 |
| Change from baseline | -6.96 ± 55.29 | 2.85 ± 58.56 |
Change from baseline (week 0) in FPG was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 7.60 ± 2.64 | 7.40 ± 2.31 |
| Change from baseline | -0.03 ± 3.19 | 0.25 ± 3.05 |
Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.
| % of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) | 20.3 | 23.3 |
Percentage of subjects reaching HbA1c \<7.0% (53 mmol/mol) without treatment emergent severe hypoglycaemic episodes was evaluated after 16 weeks of randomisation. Subjects without an HbA1c measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. Treatment emergent: hypoglycaemic episodes were defined as treatment emergent if the onset of the episode occurred on or after the first day of IMP administration after randomisation (in week 0) and no later than one day after the last day on IMP (i.e., maximum week 16 + 1 day). The results are based on the in-trial period.
| % of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Percentage of Subjects Reaching HbA1c <7.0% (53 mmol/Mol) Without Severe Hypoglycaemic Episodes | 18.6 | 22.5 |
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG \[meal test\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| 30-min (Baseline) | 10.54 ± 3.33 | 10.30 ± 2.96 |
| 1-hour (Baseline) | 12.18 ± 3.96 | 11.96 ± 3.81 |
| 2-hour (Baseline) | 13.17 ± 4.77 | 13.04 ± 4.35 |
| 3-hour (Baseline) | 11.38 ± 4.65 | 11.48 ± 4.28 |
| 4-hour (Baseline) | 9.07 ± 4.31 | 9.18 ± 3.83 |
| 30-min (Change from baseline) | -0.50 ± 4.05 | 0.42 ± 3.75 |
| 1-hour (Change from baseline) | -0.85 ± 4.65 | 0.36 ± 4.58 |
| 2-hour (Change from baseline) | -0.80 ± 5.33 | 0.42 ± 5.01 |
| 3-hour (Change from baseline) | -0.33 ± 5.12 | 0.20 ± 4.75 |
| 4-hour (Change from baseline) | 0.00 ± 4.76 | 0.21 ± 4.10 |
Change from baseline (week 0) in 30-min, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid®) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and PPG was evaluated after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| 30-min (Baseline) | 3.02 ± 2.16 | 2.95 ± 2.03 |
| 2-hour (Baseline) | 5.65 ± 4.12 | 5.70 ± 3.66 |
| 3-hour (Baseline) | 3.85 ± 4.32 | 4.13 ± 3.72 |
| 4-hour (Baseline) | 1.57 ± 4.23 | 1.83 ± 3.52 |
| 30-min (Change from baseline) | -0.53 ± 2.47 | 0.11 ± 2.25 |
| 2-hour (Change from baseline) | -0.82 ± 4.39 | 0.09 ± 4.13 |
| 3-hour (Change from baseline) | -0.35 ± 4.53 | -0.14 ± 4.07 |
| 4-hour (Change from baseline) | 0.01 ± 4.50 | -0.11 ± 3.76 |
Change from baseline (week 0) in mean of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-7-9 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 9.24 ± 1.71 | 9.10 ± 1.40 |
| Change from baseline | 0.19 ± 1.91 | 0.10 ± 1.58 |
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Breakfast (baseline) | 10.82 ± 2.99 | 10.28 ± 3.07 |
| Lunch (baseline) | 9.65 ± 3.05 | 9.62 ± 2.68 |
| Main evening meal (baseline) | 9.79 ± 3.01 | 9.34 ± 3.06 |
| Mean over all meals (baseline) | 10.07 ± 2.09 | 9.74 ± 1.99 |
| Breakfast (Change from baseline) | -0.33 ± 3.61 | 0.23 ± 3.79 |
| Lunch (Change from baseline) | 0.27 ± 3.75 | 0.05 ± 3.57 |
| Main evening meal (Change from baseline) | -0.35 ± 3.81 | 0.58 ± 3.61 |
| Mean over all meals (Change from baseline) | 0.06 ± 2.33 | 0.13 ± 2.21 |
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Breakfast (baseline) | 2.62 ± 3.16 | 1.93 ± 3.28 |
| Lunch (baseline) | 1.80 ± 2.77 | 1.77 ± 2.47 |
| Main evening meal (baseline) | 1.04 ± 3.07 | 0.52 ± 2.69 |
| Mean over all meals (baseline) | 1.93 ± 1.94 | 1.48 ± 1.86 |
| Breakfast (Change from baseline) | -0.75 ± 3.90 | 0.03 ± 3.67 |
| Lunch (Change from baseline) | -0.43 ± 3.25 | -0.27 ± 3.13 |
| Main evening meal (Change from baseline) | -0.47 ± 3.51 | 0.35 ± 3.79 |
| Mean over all meals (Change from baseline) | -0.53 ± 1.99 | 0.12 ± 1.92 |
Change from baseline (week 0) in pre-prandial PG (pre-breakfast, pre-lunch, pre-main evening meal and mean over all meals) of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Pre-breakfast (baseline) | 8.40 ± 2.50 | 8.31 ± 2.32 |
| Pre-lunch (baseline) | 8.28 ± 2.85 | 8.21 ± 2.32 |
| Pre-main evening meal (baseline) | 8.68 ± 2.76 | 8.87 ± 2.62 |
| Pre-mean over all meals (baseline) | 8.39 ± 1.73 | 8.45 ± 1.54 |
| Pre-breakfast (Change from baseline) | 0.36 ± 3.33 | 0.26 ± 3.05 |
| Pre-lunch (Change from baseline) | 0.39 ± 3.54 | 0.21 ± 3.12 |
| Pre-main evening meal (Change from baseline) | 0.15 ± 3.72 | 0.13 ± 3.18 |
| Pre-mean over all meals (Change from baseline) | 0.39 ± 2.00 | 0.21 ± 1.84 |
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-7-9 point SMPG profile at baseline (week 0) and after 16 weeks of randomisation (i.e., week 16). The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 2.14 (0.4 to 4.9) | 2.05 (0.9 to 4.0) |
| Last in-trial value | 2.06 (0.9 to 5.2) | 2.06 (0.7 to 3.8) |
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-7-9 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| 04:00 to breakfast (Baseline) | -1.29 ± 3.61 | -1.06 ± 3.35 |
| Bedtime to 04:00 (Baseline) | -0.97 ± 5.16 | -0.56 ± 3.84 |
| Bedtime to breakfast (Baseline) | -1.73 ± 4.81 | -1.56 ± 3.83 |
| 04:00 to breakfast (Change from baseline) | -0.50 ± 4.83 | -0.08 ± 4.45 |
| Bedtime to 04:00 (Change from baseline) | 0.81 ± 6.59 | 0.18 ± 5.14 |
| Bedtime to breakfast (Change from baseline) | 0.13 ± 6.67 | -0.20 ± 5.84 |
Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the in-trial period.
| % of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] | 8.1 | 7.6 |
Percentage of subjects reaching overall PPG (1 hour) ≤7.8 mmol/L \[140 mg/dL\] without treatment emergent severe hypoglycaemia was evaluated after 16 weeks of randomisation. Subjects without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal was considered sufficient evidence that the event was induced by a low PG concentration. The results are based on the in-trial period.
| % of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Percentage of Subjects Reaching Overall PPG (1 Hour) ≤7.8 mmol/L [140 mg/dL] Without Severe Hypoglycaemia | 7.6 | 6.8 |
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values at baseline (week 0) and after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Total cholesterol (Baseline) | 4.48 (2.6 to 8.1) | 4.68 (2.9 to 8.0) |
| High density lipoproteins (Baseline) | 1.70 (0.8 to 3.3) | 1.71 (0.8 to 3.8) |
| Low density lipoproteins (Baseline) | 2.46 (1.1 to 6.4) | 2.63 (1.2 to 6.6) |
| Total cholesterol (Last in-trial value) | 4.61 (2.8 to 7.2) | 4.57 (2.4 to 8.2) |
| High density lipoproteins (Last in-trial value) | 1.74 (0.9 to 3.1) | 1.74 (0.7 to 3.6) |
| Low density lipoproteins (Last in-trial value) | 2.56 (1.0 to 5.2) | 2.59 (1.1 to 6.4) |
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised trial products (faster aspart and NovoRapid®) to no later than 7 days after the day of last dose of randomised trial products.
| Unit (U) | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/Day: Total Basal | 23.82 ± 12.82 | 23.87 ± 11.38 |
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/Day: Total Bolus | 25.91 ± 17.46 | 25.27 ± 15.33 |
Total insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/Day: Total Daily Insulin Dose | 49.72 ± 27.08 | 49.12 ± 23.75 |
No data was collected for individual meal insulin dose.
No measurements were reported for this outcome.
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/Kg | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/kg/Day: Total Basal | 0.30 ± 0.12 | 0.30 ± 0.11 |
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/Kg | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/kg/Day: Total Bolus | 0.33 ± 0.17 | 0.31 ± 0.16 |
Total insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/Kg | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Dose in Units/kg/Day: Total Daily Insulin Dose | 0.63 ± 0.24 | 0.61 ± 0.23 |
No data was collected for individual meal insulin dose.
No measurements were reported for this outcome.
Insulin carbohydrate ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Gram (g)/U | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Delivery Pump Parameter: Insulin Carbohydrate Ratio | 9.13 ± 3.20 | 9.74 ± 6.77 |
Glucose sensitivity factor was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mmol/L/U | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Delivery Pump Parameter: Glucose Sensitivity Factor | 2.65 ± 1.14 | 2.60 ± 0.98 |
Active insulin time was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Hour (h) | Faster Aspart | NovoRapid |
|---|---|---|
| Insulin Delivery Pump Parameter: Active Insulin Time | 3.6 ± 0.7 | 3.6 ± 0.7 |
Change from baseline (week 0) in mean interstitial glucose (IG) increment (0-30 minutes (min), 0-1 hour (h) and 0-2 h after start of meal) (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Breakfast 0-30 min (Baseline) | 0.23 ± 0.61 | 0.21 ± 0.60 |
| Lunch 0-30 min (Baseline) | 0.02 ± 0.54 | 0.03 ± 0.60 |
| Main evening meal 0-30 min (Baseline) | 0.15 ± 0.52 | 0.09 ± 0.57 |
| Mean across all meals 0-30 min (Baseline) | 0.13 ± 0.37 | 0.11 ± 0.39 |
| Breakfast 0-1 h (Baseline) | 0.78 ± 0.97 | 0.73 ± 0.94 |
| Lunch 0-1 h (Baseline) | 0.42 ± 0.77 | 0.44 ± 0.84 |
| Main evening meal 0-1 h (Baseline) | 0.39 ± 0.75 | 0.32 ± 0.82 |
| Mean across all meals 0-1 h (Baseline) | 0.52 ± 0.57 | 0.50 ± 0.60 |
| Breakfast 0-2 h (Baseline) | 1.32 ± 1.52 | 1.27 ± 1.46 |
| Lunch 0-2 h (Baseline) | 0.99 ± 1.19 | 0.92 ± 1.07 |
| Main evening meal 0-2 h (Baseline) | 0.54 ± 1.15 | 0.50 ± 1.19 |
| Mean across all meals 0-2 h (Baseline) | 0.93 ± 0.94 | 0.89 ± 0.84 |
| Breakfast 0-30 min (Change from baseline) | -0.03 ± 0.80 | 0.08 ± 0.67 |
| Lunch 0-30 min (Change from baseline) | 0.05 ± 0.61 | 0.10 ± 0.68 |
| Main evening meal 0-30 min (Change from baseline) | -0.07 ± 0.73 | -0.01 ± 0.70 |
| Mean across all meals 0-30min:Change from baseline | -0.01 ± 0.46 | 0.06 ± 0.46 |
| Breakfast 0-1 h (Change from baseline) | -0.13 ± 1.13 | 0.14 ± 0.99 |
| Lunch 0-1 h (Change from baseline) | -0.02 ± 0.88 | 0.15 ± 0.99 |
| Main evening meal 0-1 h (Change from baseline) | -0.16 ± 0.95 | 0.04 ± 0.97 |
| Mean across all meals 0-1 h (Change from baseline) | -0.10 ± 0.61 | 0.11 ± 0.66 |
| Breakfast 0-2 h (Change from baseline) | -0.28 ± 1.60 | 0.16 ± 1.45 |
| Lunch 0-2 h (Change from baseline) | -0.24 ± 1.32 | 0.22 ± 1.37 |
| Main evening meal 0-2 h (Change from baseline) | -0.29 ± 1.29 | -0.03 ± 1.27 |
| Mean across all meals 0-2 h (Change from baseline) | -0.25 ± 0.81 | 0.12 ± 0.86 |
Change from baseline (week 0) in mean time to the IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| Minutes | Faster Aspart | NovoRapid |
|---|---|---|
| Breakfast (Baseline) | 88.95 ± 25.66 | 97.29 ± 32.32 |
| Lunch (Baseline) | 109.47 ± 31.78 | 106.94 ± 29.67 |
| Main evening meal (Baseline) | 110.11 ± 32.35 | 106.91 ± 29.61 |
| Mean across all meals (Baseline) | 103.24 ± 18.50 | 103.99 ± 19.21 |
| Breakfast (Change from baseline) | 0.25 ± 33.69 | -4.03 ± 35.49 |
| Lunch (Change from baseline) | -2.00 ± 38.63 | 1.64 ± 38.02 |
| Main evening meal (Change from baseline) | -2.04 ± 40.51 | -1.43 ± 38.94 |
| Mean across all meals (Change from baseline) | -1.30 ± 22.01 | -1.00 ± 21.90 |
Change from baseline (week 0) in mean IG peak after start of meal (breakfast, lunch, main evening meal and mean across all meals) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Breakfast (Baseline) | 12.43 ± 1.97 | 12.25 ± 2.09 |
| Lunch (Baseline) | 12.42 ± 2.07 | 12.56 ± 1.84 |
| Main evening meal (Baseline) | 12.65 ± 2.10 | 12.70 ± 2.06 |
| Mean across all meals (Baseline) | 12.49 ± 1.67 | 12.51 ± 1.60 |
| Breakfast (Change from baseline) | 0.10 ± 2.24 | 0.11 ± 2.11 |
| Lunch (Change from baseline) | 0.10 ± 2.19 | 0.19 ± 1.92 |
| Main evening meal (Change from baseline) | 0.22 ± 2.09 | -0.13 ± 2.14 |
| Mean across all meals (Change from baseline) | 0.16 ± 1.63 | 0.03 ± 1.59 |
Percentage of time spent with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| % of time | Faster Aspart | NovoRapid |
|---|---|---|
| IG ≤2.5 mmol/L (45 mg/dL) | 1.11 ± 1.29 | 1.03 ± 1.38 |
| IG ≤3.0 mmol/L (54 mg/dL) | 2.15 ± 1.98 | 2.19 ± 2.25 |
| IG ≤3.5 mmol/L (63 mg/dL) | 3.75 ± 2.85 | 3.93 ± 3.37 |
| IG ≤3.9 mmol/L (70.2 mg/dL) | 5.46 ± 3.68 | 5.76 ± 4.25 |
| IG >10.0 mmol/L (180 mg/dL) | 41.57 ± 13.09 | 39.24 ± 11.86 |
| IG >12.0 mmol/L (216 mg/dL) | 26.34 ± 11.66 | 24.23 ± 10.75 |
| IG >13.9 mmol/L (250 mg/dL) | 15.87 ± 9.42 | 14.23 ± 8.49 |
Incidence of episodes with IG ≤2.5, 3.0, 3.5, 3.9 mmol/L \[45, 54, 63, 70 mg/dL\]) and IG \>10.0, 12.0, 13.9 mmol/L \[180, 216, 250 mg/dL\]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| Number of Events | Faster Aspart | NovoRapid |
|---|---|---|
| IG ≤2.5 mmol/L (45 mg/dL) | 1570 | 1532 |
| IG ≤3.0 mmol/L (54 mg/dL) | 2848 | 2920 |
| IG ≤3.5 mmol/L (63 mg/dL) | 4584 | 4742 |
| IG ≤3.9 mmol/L (70 mg/dL) | 6371 | 6576 |
| IG >10.0 mmol/L (180 mg/dL) | 35194 | 33176 |
| IG >12.0 mmol/L (216 mg/dL) | 23070 | 21276 |
| IG >13.9 mmol/L (250 mg/dL) | 14352 | 12866 |
Change from baseline (week 0) in mean of the IG profile was evaluated after 16 weeks of randomisation. The mean of an IG profile is defined as the time integral of the profile over the profile's length, divided by the profile's length. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 9.38 ± 1.18 | 9.39 ± 1.20 |
| Change from baseline | 0.28 ± 1.27 | 0.04 ± 1.18 |
Percentage of time spent within IG target range 4.0-7.8 mmol/L (71-140 mg/dL) and 4.0-10 mmol/L (71-180 mg/dL) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| % of time | Faster Aspart | NovoRapid |
|---|---|---|
| IG 4.0-7.8 mmol/L (71-140 mg/dL) | 31.49 ± 9.97 | 33.11 ± 8.76 |
| IG 4.0-10.0 mmol/L (71-180 mg/dL) | 52.40 ± 11.87 | 54.40 ± 10.70 |
Variation in IG profile was the average absolute difference from the mean of the IG profile. Variation in the IG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Variation in the IG Profile | 3.09 (1.6 to 5.6) | 3.04 (1.6 to 5.1) |
Area under the curve (AUC3.9-IG) for IG ≤3.9 mmol/L \[70 mg/dL\] was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Area Under the Curve (AUC3.9-IG) for IG ≤3.9 mmol/L [70 mg/dL] | 3.19 ± 0.22 | 3.21 ± 0.20 |
Change from baseline (week 0) in area under the curve for interstitial glucose (AUCIG),0-15 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 7.55 ± 2.63 | 7.37 ± 2.20 |
| Change from baseline | 0.16 ± 3.06 | 0.21 ± 2.96 |
Change from baseline (week 0) in AUCIG,0-30 minutes during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 7.98 ± 2.65 | 7.86 ± 2.25 |
| Change from baseline | 0.12 ± 3.12 | 0.22 ± 3.02 |
Change from baseline (week 0) in AUCIG,0-1 hour during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 9.47 ± 2.76 | 9.35 ± 2.38 |
| Change from baseline | -0.07 ± 3.33 | 0.32 ± 3.26 |
Change from baseline (week 0) in AUCIG,0-2 hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 11.27 ± 3.10 | 11.18 ± 2.82 |
| Change from baseline | -0.38 ± 3.76 | 0.37 ± 3.90 |
Change from baseline (week 0) in AUCIG,0-24hours during meal test was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 11.31 ± 3.33 | 11.40 ± 3.03 |
| Change from baseline | -0.32 ± 4.07 | 0.29 ± 4.10 |
Change from baseline (week 0) in time to the IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| Minute | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 111.2 ± 45.3 | 117.0 ± 43.0 |
| Change from baseline | 1.2 ± 50.5 | -1.4 ± 51.6 |
Change from baseline (week 0) in IG peak after start of meal-test meal was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 14.71 ± 3.94 | 14.69 ± 3.65 |
| Change from baseline | -0.57 ± 4.69 | 0.36 ± 4.78 |
Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 16. A TEAE was defined as an event that has an onset date on or after the first day of exposure to randomised treatment (in week 0), and no later than seven days after the last day of randomised treatment (i.e., maximum week 16 + 7 days). The results are based on the on-treatment period.
| Number of adverse events | Faster Aspart | NovoRapid |
|---|---|---|
| Number of Treatment Emergent Adverse Events (AEs) | 440 | 412 |
Number of treatment emergent infusion site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period.
| Number of infusion site reaction events | Faster Aspart | NovoRapid |
|---|---|---|
| Number of Treatment Emergent Infusion Site Reactions | 44 | 32 |
ADA classification of hypo: 1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. 2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. 3. Asymptomatic: PG ≤3.9 mmol/L without symptoms. 4. Probable symptomatic: No measurement with symptoms. 5. Pseudo: PG \>3.9 mmol/L with symptoms. 6. Unclassifiable. NN classification of hypo: 1. BG confirmed: PG \<3.1 mmol/L with/without symptoms. 2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with symptoms. 3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG \<3.1 mmol/L with/without symptoms. 4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypo.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 21 | 7 |
| ADA: Documented symptomatic | 8372 | 8904 |
| ADA: Asymptomatic | 2530 | 2273 |
| ADA: Probable symptomatic | 88 | 32 |
| ADA: Pseudo | 56 | 159 |
| ADA: Unclassifiable | 1 | 0 |
| NN: BG confirmed | 3258 | 3240 |
| NN: Severe or BG confirmed symptomatic | 2751 | 2779 |
| NN: Severe or BG confirmed | 3279 | 3247 |
| NN: Unclassifiable | 7789 | 8128 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 12 | 5 |
| ADA: Documented symptomatic | 7508 | 7889 |
| ADA: Asymptomatic | 2321 | 2071 |
| ADA: Probable symptomatic | 70 | 26 |
| ADA: Pseudo | 52 | 144 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 2799 | 2769 |
| NN: Severe or BG confirmed symptomatic | 2335 | 2359 |
| NN: Severe or BG confirmed | 2811 | 2774 |
| NN: Unclassifiable | 7152 | 7361 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 9 | 2 |
| ADA: Documented symptomatic | 864 | 1015 |
| ADA: Asymptomatic | 209 | 202 |
| ADA: Probable symptomatic | 18 | 6 |
| ADA: Pseudo | 4 | 15 |
| ADA: Unclassifiable | 1 | 0 |
| NN: BG confirmed | 459 | 471 |
| NN: Severe or BG confirmed symptomatic | 416 | 420 |
| NN: Severe or BG confirmed | 468 | 473 |
| NN: Unclassifiable | 637 | 767 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 0 | 0 |
| ADA: Documented symptomatic | 224 | 190 |
| ADA: Asymptomatic | 31 | 33 |
| ADA: Probable symptomatic | 1 | 3 |
| ADA: Pseudo | 0 | 5 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 92 | 51 |
| NN: Severe or BG confirmed symptomatic | 81 | 48 |
| NN: Severe or BG confirmed | 92 | 51 |
| NN: Unclassifiable | 164 | 180 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 0 | 0 |
| ADA: Documented symptomatic | 1258 | 1077 |
| ADA: Asymptomatic | 176 | 175 |
| ADA: Probable symptomatic | 9 | 6 |
| ADA: Pseudo | 7 | 34 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 482 | 413 |
| NN: Severe or BG confirmed symptomatic | 441 | 372 |
| NN: Severe or BG confirmed | 482 | 413 |
| NN: Unclassifiable | 968 | 879 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 5 | 2 |
| ADA: Documented symptomatic | 3767 | 3907 |
| ADA: Asymptomatic | 750 | 677 |
| ADA: Probable symptomatic | 43 | 17 |
| ADA: Pseudo | 29 | 98 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 1403 | 1399 |
| NN: Severe or BG confirmed symptomatic | 1246 | 1259 |
| NN: Severe or BG confirmed | 1408 | 1401 |
| NN: Unclassifiable | 3186 | 3300 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 5 | 2 |
| ADA: Documented symptomatic | 2509 | 2830 |
| ADA: Asymptomatic | 574 | 502 |
| ADA: Probable symptomatic | 34 | 11 |
| ADA: Pseudo | 22 | 64 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 921 | 986 |
| NN: Severe or BG confirmed symptomatic | 805 | 887 |
| NN: Severe or BG confirmed | 926 | 988 |
| NN: Unclassifiable | 2218 | 2421 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 1 hour to 2 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 0 | 0 |
| ADA: Documented symptomatic | 1034 | 887 |
| ADA: Asymptomatic | 145 | 142 |
| ADA: Probable symptomatic | 8 | 3 |
| ADA: Pseudo | 7 | 29 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 390 | 362 |
| NN: Severe or BG confirmed symptomatic | 360 | 324 |
| NN: Severe or BG confirmed | 390 | 362 |
| NN: Unclassifiable | 804 | 699 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 3 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 2 | 1 |
| ADA: Documented symptomatic | 1327 | 1518 |
| ADA: Asymptomatic | 277 | 241 |
| ADA: Probable symptomatic | 19 | 7 |
| ADA: Pseudo | 13 | 38 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 491 | 555 |
| NN: Severe or BG confirmed symptomatic | 429 | 508 |
| NN: Severe or BG confirmed | 493 | 556 |
| NN: Unclassifiable | 1145 | 1249 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 3 to 4 hours after start of the meal. The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| ADA: Severe | 3 | 1 |
| ADA: Documented symptomatic | 1182 | 1312 |
| ADA: Asymptomatic | 297 | 261 |
| ADA: Probable symptomatic | 15 | 4 |
| ADA: Pseudo | 9 | 26 |
| ADA: Unclassifiable | 0 | 0 |
| NN: BG confirmed | 430 | 431 |
| NN: Severe or BG confirmed symptomatic | 376 | 379 |
| NN: Severe or BG confirmed | 433 | 432 |
| NN: Unclassifiable | 1073 | 1172 |
| Not able to selftreat - unclassifiable | 0 | 0 |
Unexplained hyperglycaemia was defined as a confirmed PG value ≥16.7 mmol/L (300 mg/dL) and was unexplained (i.e. no apparent medical, dietary, insulin dosage or pump failure reason). The results are based on the on-treatment period.
| Number of hypoglycaemic episodes | Faster Aspart | NovoRapid |
|---|---|---|
| Number of Unexplained Episodes of Hyperglycaemia (Confirmed by SMPG) | 1185 | 1058 |
Reported results are respiratory system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 234 | 235 |
| Abnormal (NCS), baseline | 1 | 1 |
| Abnormal (CS), baseline | 1 | 0 |
| Normal, last on-treatment value | 235 | 234 |
| Abnormal (NCS), last on-treatment value | 0 | 2 |
| Abnormal (CS), last on-treatment value | 1 | 0 |
Reported results are cardiovascular system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 233 | 229 |
| Abnormal (NCS), baseline | 1 | 7 |
| Abnormal (CS), baseline | 2 | 0 |
| Normal, last on-treatment value | 231 | 228 |
| Abnormal (NCS), last on-treatment value | 4 | 7 |
| Abnormal (CS), last on-treatment value | 1 | 1 |
Reported results are central and peripheral nervous system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 210 | 215 |
| Abnormal (NCS), baseline | 22 | 18 |
| Abnormal (CS), baseline | 4 | 3 |
| Normal, last on-treatment value | 209 | 216 |
| Abnormal (NCS), last on-treatment value | 23 | 17 |
| Abnormal (CS), last on-treatment value | 4 | 3 |
Reported results are gastrointestinal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 231 | 231 |
| Abnormal (NCS), baseline | 3 | 5 |
| Abnormal (CS), baseline | 2 | 0 |
| Normal, last on-treatment value | 231 | 231 |
| Abnormal (NCS), last on-treatment value | 4 | 3 |
| Abnormal (CS), last on-treatment value | 1 | 2 |
Reported results are musculoskeletal system-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 222 | 227 |
| Abnormal (NCS), baseline | 13 | 9 |
| Abnormal (CS), baseline | 1 | 0 |
| Normal, last on-treatment value | 223 | 228 |
| Abnormal (NCS), last on-treatment value | 12 | 8 |
| Abnormal (CS), last on-treatment value | 1 | 0 |
Reported results are skin-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 212 | 211 |
| Abnormal (NCS), baseline | 18 | 22 |
| Abnormal (CS), baseline | 6 | 3 |
| Normal, last on-treatment value | 204 | 203 |
| Abnormal (NCS), last on-treatment value | 21 | 29 |
| Abnormal (CS), last on-treatment value | 11 | 4 |
Reported results are head, ears, eyes, nose, throat and neck-examination findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, baseline | 219 | 221 |
| Abnormal (NCS), baseline | 15 | 14 |
| Abnormal (CS), baseline | 2 | 1 |
| Normal, last on-treatment value | 217 | 218 |
| Abnormal (NCS), last on-treatment value | 15 | 16 |
| Abnormal (CS), last on-treatment value | 4 | 2 |
Change from baseline (week 0) in blood pressure (both systolic and diastolic) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mmHg | Faster Aspart | NovoRapid |
|---|---|---|
| Systolic blood pressure (baseline) | 123.6 ± 14.7 | 122.0 ± 14.3 |
| Diastolic blood pressure (baseline) | 74.8 ± 9.4 | 74.6 ± 8.7 |
| Systolic blood pressure (change from baseline) | -0.8 ± 12.3 | -0.7 ± 11.5 |
| Diastolic blood pressure (change from baseline) | -0.7 ± 8.4 | -0.4 ± 7.7 |
Change from baseline (week 0) in pulse was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Beats/minute | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 73.7 ± 11.0 | 74.5 ± 11.1 |
| Change from baseline | -0.5 ± 9.0 | -0.8 ± 9.6 |
Reported results are ECG findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) Abnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Normal, screening | 178 | 181 |
| Abnormal (NCS), screening | 58 | 54 |
| Abnormal (CS), screening | 0 | 1 |
| Normal, last on-treatment value | 188 | 180 |
| Abnormal (NCS), last on-treatment value | 44 | 48 |
| Abnormal (CS), last on-treatment value | 0 | 2 |
Reported results are fundus photography/fundoscopy (for both left and right eye) findings at screening (week -6) and after 16 weeks of randomisation. The findings are presented as: 1) Normal. 2) AAbnormal (not clinically significant \[NCS\]). 3) Abnormal (clinically significant \[CS\]). The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Left eye (Normal), screening | 135 | 136 |
| Left eye (Abnormal [NCS]), screening | 94 | 94 |
| Left eye (Abnormal [CS]), screening | 7 | 6 |
| Right eye (Normal), screening | 132 | 132 |
| Right eye (Abnormal [NCS]), screening | 98 | 98 |
| Right eye (Abnormal [CS]), screening | 6 | 6 |
| Left eye (Normal), last on-treatment value | 130 | 119 |
| Left eye (Abnormal [NCS]), last on-treatment value | 77 | 82 |
| Left eye (Abnormal [CS] last on-treatment value | 10 | 7 |
| Right eye (Normal), last on-treatment value | 127 | 114 |
| Right eye (Abnormal-NCS), last on-treatment value | 80 | 87 |
| Right eye (Abnormal [CS]), last on-treatment value | 10 | 7 |
Change from baseline (week 0) in haemoglobin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 8.62 ± 0.82 | 8.62 ± 0.80 |
| Change from baseline | -0.01 ± 0.48 | -0.06 ± 0.40 |
Change from baseline (week 0) in haematocrit was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| % of haematocrit | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 42.23 ± 3.98 | 42.37 ± 3.77 |
| Change from baseline | 0.09 ± 2.47 | -0.30 ± 2.01 |
Change from baseline (week 0) in erythrocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| 10^12/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 4.66 ± 0.45 | 4.72 ± 0.42 |
| Change from baseline | 0.01 ± 0.27 | -0.03 ± 0.22 |
Change from baseline (week 0) in thrombocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| 10^9/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 246.4 ± 58.9 | 243.6 ± 55.3 |
| Change from baseline | 2.2 ± 33.5 | 0.2 ± 35.8 |
Change from baseline (week 0) in leucocytes was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| 10^9/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 6.41 ± 1.78 | 6.32 ± 1.70 |
| Change from baseline | -0.09 ± 1.49 | -0.03 ± 1.22 |
Change from baseline (week 0) in total protein was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| g/dL | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 6.73 ± 0.44 | 6.74 ± 0.47 |
| Change from baseline | 0.03 ± 0.36 | -0.05 ± 0.40 |
Change from baseline (week 0) in creatinine was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| umol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 73.8 ± 12.3 | 74.5 ± 13.3 |
| Change from baseline | 0.9 ± 7.9 | -0.1 ± 8.2 |
Change from baseline (week 0) in ALT was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 20.0 ± 11.6 | 19.1 ± 11.5 |
| Change from baseline | 0.1 ± 13.8 | 0 ± 9.4 |
Change from baseline (week 0) in AST was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 22.2 ± 9.1 | 20.6 ± 7.8 |
| Change from baseline | -0.1 ± 18.6 | -0.4 ± 8.7 |
Change from baseline (week 0) in ALP was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| U/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 68.8 ± 20.8 | 69.7 ± 23.9 |
| Change from baseline | 1.2 ± 9.6 | 0.8 ± 10.0 |
Change from baseline (week 0) in sodium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 140.3 ± 2.7 | 140.3 ± 2.7 |
| Change from baseline | -0.2 ± 2.9 | -0.2 ± 2.5 |
Change from baseline (week 0) in potassium was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mmol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 4.34 ± 0.42 | 4.30 ± 0.39 |
| Change from baseline | -0.02 ± 0.42 | -0.01 ± 0.41 |
Change from baseline (week 0) in albumin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| g/dL | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 4.32 ± 0.27 | 4.31 ± 0.28 |
| Change from baseline | -0.01 ± 0.22 | -0.05 ± 0.26 |
Change from baseline (week 0) in bilirubin was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| umol/L | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 8.2 ± 5.1 | 8.8 ± 6.4 |
| Change from baseline | -0.3 ± 3.8 | -1.0 ± 3.7 |
Change from baseline (week 0) in albumin/creatine ratio was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| mg/mmol | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 2.67 ± 13.88 | 2.00 ± 7.60 |
| Change from baseline | 0.01 ± 4.76 | -0.04 ± 3.11 |
Reported results are urine erythrocytes-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ and e) 3+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Negative (baseline) | 217 | 215 |
| Trace (baseline) | 8 | 10 |
| 1+ (baseline) | 5 | 5 |
| 2+ (baseline) | 5 | 1 |
| 3+ (baseline) | 1 | 5 |
| Negative (last on-treatment value) | 217 | 215 |
| Trace (last on-treatment value) | 6 | 10 |
| 1+ (last on-treatment value) | 3 | 3 |
| 2+ (last on-treatment value) | 2 | 4 |
| 3+ (last on-treatment value) | 8 | 4 |
Reported results are urine protein-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Negative (baseline) | 193 | 195 |
| Trace (baseline) | 31 | 27 |
| 1+ (baseline) | 8 | 10 |
| 2+ (baseline) | 4 | 4 |
| 3+ (baseline) | 0 | 0 |
| 4+ (baseline) | 0 | 0 |
| Negative (last on-treatment value) | 196 | 196 |
| Trace (last on-treatment value) | 27 | 27 |
| 1+ (last on-treatment value) | 10 | 9 |
| 2+ (last on-treatment value) | 2 | 4 |
| 3+ (last on-treatment value) | 1 | 0 |
| 4+ (last on-treatment value) | 0 | 0 |
Reported results are urine ketone-test findings at baseline (week 0) and after 16 weeks of randomisation. The findings are presented as: a) Negative, b) Trace, c) 1+, d) 2+ e) 3+ and f) 4+. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Negative (baseline) | 192 | 205 |
| Trace (baseline) | 31 | 23 |
| 1+ (baseline) | 11 | 8 |
| 2+ (baseline) | 2 | 0 |
| 3+ (baseline) | 0 | 0 |
| 4+ (baseline) | 0 | 0 |
| Negative (last on-treatment value) | 194 | 203 |
| Trace (last on-treatment value) | 25 | 27 |
| 1+ (last on-treatment value) | 15 | 5 |
| 2+ (last on-treatment value) | 2 | 1 |
| 3+ (last on-treatment value) | 0 | 0 |
| 4+ (last on-treatment value) | 0 | 0 |
Change from baseline (week 0) in body weight was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Kg | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 76.86 ± 15.20 | 78.21 ± 14.47 |
| Change from baseline | 0.34 ± 1.90 | 0.80 ± 2.14 |
Change from baseline (week 0) in BMI was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| kg/m^2 | Faster Aspart | NovoRapid |
|---|---|---|
| Baseline | 26.16 ± 4.06 | 26.51 ± 3.89 |
| Change from baseline | 0.12 ± 0.65 | 0.28 ± 0.74 |
Number of change-of-infusion-sets per week was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period.
| Number of infusion-sets | Faster Aspart | NovoRapid |
|---|---|---|
| Number of Change-of-infusion-sets Per Week | 2.55 ± 0.43 | 2.49 ± 0.47 |
Number of subjects with at least one non-routine change-of-infusion-sets categorised by reasons for change-of-infusion-sets was evaluated from week 0 to week 16. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. Reasons for change-of-infusion-sets are categorised as follows: Category-1: A perceived occlusion by the subject Category-2: Any problems related to the infusion set Category-3: Any technical issues with the pump Category-4: Changes in the insulin solution in the infusion set or reservoir Category-5: High BG with no other explanation which made the subject change the infusion set Category-6: Infusion site reaction Category-7: Missing
| Number of subjects | Faster Aspart | NovoRapid |
|---|---|---|
| Category-1 | 50 | 50 |
| Category-2 | 108 | 75 |
| Category-3 | 23 | 17 |
| Category-4 | 3 | 8 |
| Category-5 | 66 | 60 |
| Category-6 | 16 | 8 |
| Category-7 | 3 | 1 |
Collected over Week 0 to Week 16 + 7 days. All reported AEs are treatment emergent (i.e., TEAE).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faster Aspart | 0/236 (0%) | 5/236 (2.1%) | 84/236 (35.6%) |
| NovoRapid | 0/236 (0%) | 8/236 (3.4%) | 72/236 (30.5%) |
| Event | Faster Aspart | NovoRapid |
|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 0/236 | 1/236 |
| Adenovirus infectionInfections and infestations | 0/236 | 1/236 |
| AppendicitisInfections and infestations | 1/236 | 0/236 |
| Device breakageProduct Issues | 0/236 | 1/236 |
| Drug eruptionSkin and subcutaneous tissue disorders | 1/236 | 0/236 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/236 | 1/236 |
| Hypoglycaemic seizureNervous system disorders | 0/236 | 1/236 |
| Hypoglycaemic unconsciousnessNervous system disorders | 1/236 | 1/236 |
| KetoacidosisMetabolism and nutrition disorders | 1/236 | 0/236 |
| NeurodermatitisSkin and subcutaneous tissue disorders | 0/236 | 1/236 |
| Event | Faster Aspart | NovoRapid |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 48/236 | 50/236 |
| Upper respiratory tract infectionInfections and infestations | 17/236 | 12/236 |
| Infusion site reactionGeneral disorders | 16/236 | 7/236 |
| GastroenteritisInfections and infestations | 12/236 | 6/236 |
| Age, Continuous(Years) | Faster Aspart | NovoRapid | Total |
|---|---|---|---|
| Mean | 43.3 ± 14.8 | 43.6 ± 14.7 | 43.5 ± 14.7 |
| Sex: Female, Male(Participants) | Faster Aspart | NovoRapid | Total |
|---|---|---|---|
| Female | 133 | 136 | 269 |
| Male | 103 | 100 | 203 |
| Ethnicity (NIH/OMB)(Participants) | Faster Aspart | NovoRapid | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 13 |
| Not Hispanic or Latino | 210 | 215 | 425 |
| Unknown or Not Reported | 19 | 15 | 34 |
| Race (NIH/OMB)(Participants) | Faster Aspart | NovoRapid | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 3 | 3 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 209 | 210 | 419 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 22 | 16 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2016 to primary completion in Jun 2017, 11 months.
Results were first posted in Jul 2018, 1 year 1 month after primary completion.
Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 11 months is below that.
Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Aspart